Compare Abeona Therapeutics Inc (ABEO) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AST SpaceMobile Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while AST SpaceMobile Inc trades at $75.09 (market cap $22.17B). The key difference: AST SpaceMobile Inc is far larger — about 59.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ASTS | |
|---|---|---|
Market Cap | $373.32M | $22.17B |
Sector | Health | Media |
52-Week High | $7.23 | $133.09 |
52-Week Low | $4.17 | $36.91 |
Enterprise Value | $228.22M | $22.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AST SpaceMobile (ASTS) trades at $74.21, down 12.83% in the last session amid a broader space stock selloff. The stock shows bearish technical signals with negative earnings surprises and deeply negative profitability margins. Recent news highlights satellite launch progress and competitive pressures from SpaceX, while cash flow remains heavily dependent on financing activities to fund operations and capital expenditures.
Outlook remains speculative with high execution risk; revenue growth is overshadowed by persistent losses and cash burn. Analyst consensus is mixed with a $84 price target offering potential upside, but investors face significant dilution risk and competitive threats in the nascent satellite broadband market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
